Date: 2017-01-05
Type of information: Series B financing round
Company: Neon Therapeutics (USA - MA)
Investors:
Amount: $70 million
Funding type: series B financing round
Planned used:
- Proceeds from the financing will be used to advance Neon Therapeutics’ lead program NEO-PV-01, a fully personalized neoantigen vaccine, through an ongoing Phase 1b clinical trial. In addition, this investment will support preclinical development of NEOPTC-01, a personalized adoptive T cell program, and the Shared Neoantigen Program.
Others:
- • On January 5, 2017, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced the successful completion of a $70 million Series B financing. The Series B financing was led by Partner Fund Management. Joined by existing investors Third Rock Ventures and Access Industries, additional new investors included Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures and Nextech Invest.
Therapeutic area: Cancer - Oncology
Is general: Yes
